Wijk, Marie;
Denti, Paolo;
Gausi, Kamunkhwala;
Myers, Bronwyn;
Carney, Tara;
White, Laura F;
Theron, Danie;
... Kloprogge, Frank; + view all
(2025)
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.
Clinical Infectious Diseases
, Article ciaf586. 10.1093/cid/ciaf586.
(In press).
Preview |
Text
ciaf586.pdf - Accepted Version Download (1MB) | Preview |
Abstract
BACKGROUND: Quantitative markers of tuberculosis disease burden are essential for assessing treatment response and optimizing therapeutic strategies. This study evaluated the impact of antimicrobial plasma drug levels on time-to-positivity (TTP) trajectories in patients with drug-susceptible tuberculosis and explored the relationship between bacillary clearance and treatment outcomes. METHODS: Patients with drug susceptible pulmonary tuberculosis initiating treatment were recruited in Worcester, South Africa. Weekly sputum samples were collected for 12 weeks, with bacterial load quantified using Mycobacterial Growth Indicator Tubes, yielding TTP. Nonlinear mixed-effects modeling was used to empirically describe longitudinal TTP, assessing rifampicin exposure and other participant characteristics as covariates. TTP trajectories were stratified by treatment outcomes to identify trends between change in TTP and outcome. RESULTS: 402 participants were included, of whom 60% were male. Median age was 37 years (IQR 26-48) and 90% had successful treatment outcomes (were cured or completed treatment) at 6 months with 3% who experienced treatment failure, 2% died, 1% transferred and 4% were lost to follow-up. Baseline smear grade and lung cavitation decreased baseline TTP. Higher rifampicin concentration area under the curve (AUC) was associated with faster longitudinal change in TTP, while lung cavitation and older age were associated with slower longitudinal change. Further, slower change in TTP during the first 12 weeks of treatment was linked to treatment failure at six months. CONCLUSION: Our findings highlight the role of rifampicin plasma exposure in optimizing bacillary clearance and improving treatment outcomes, even within standard dosing regimens for drug-susceptible tuberculosis.
| Type: | Article |
|---|---|
| Title: | Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/cid/ciaf586 |
| Publisher version: | https://doi.org/10.1093/cid/ciaf586 |
| Language: | English |
| Additional information: | © The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| Keywords: | bacillary clearance, pharmacokinetics-pharmacodynamics, rifampicin exposure, treatment outcome, tuberculosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10216711 |
Archive Staff Only
 |
View Item |
